Overview

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

Status:
Enrolling by invitation
Trial end date:
2024-02-01
Target enrollment:
0
Participant gender:
All
Summary
Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kadmon Corporation, LLC
Criteria
Inclusion Criteria:

Subjects must have been treated with belumosudil for at least 1 of the following:

- Actively receiving belumosudil on Study KD025-208 or Study KD025-213

- Is in Long-term Follow-up (LTFU) on Study KD025-208 or Study KD025-213. Long-term
Follow-up will be defined as the period after ending treatment with belumosudil and
until a FFS event occurs.

- Adult enrolled in the Companion Study under KD025-213 Amendment 2 (01 June 2020) and
has received at least 6 months of treatment of belumosudil or is in LTFU

Exclusion Criteria:

- Female subject who is pregnant or breastfeeding

- Subject considered unlikely to adhere to treatment and/or follow protocol in the
opinion of the Investigator